We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$319M
AUM Growth
+$70.9M
Cap. Flow
+$46.8M
Cap. Flow %
14.67%
Top 10 Hldgs %
84.89%
Holding
29
New
5
Increased
1
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$31.8M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$9.8M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$6.6M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
2
BYSI icon
BeyondSpring
BYSI
+$5.55M
3
ATRC icon
AtriCure
ATRC
+$1.92M
4
ACET icon
Adicet Bio
ACET
+$410K
5
OWLT icon
Owlet
OWLT
+$291K

Sector Composition

Rank Sector Weight
1 Healthcare 71.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALP.PRN
1
DELISTED
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
$69M 21.63%
6,708,288
– –
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$356M
$59.2M 18.58%
2,099,583
+275,000
+15% +$6.6M
SLRN
3
DELISTED
ACELYRIN
SLRN
$32.5M 10.19%
+1,554,417
New +$31.8M
TXG icon
4
10x Genomics
TXG
$5.79B
$20.1M 6.3%
359,554
– –
PACB icon
5
Pacific Biosciences
PACB
$363M
$19.5M 6.11%
1,463,872
– –
RCUS icon
6
Arcus Biosciences
RCUS
$3.56B
$17.7M 5.54%
869,790
– –
ILMN icon
7
Illumina
ILMN
$29.3B
$15.2M 4.76%
83,123
– –
PHAT icon
8
Phathom Pharmaceuticals
PHAT
$679M
$12.2M 3.82%
+850,000
New +$9.8M
ARGX icon
9
argenx
ARGX
$54.8B
$10.7M 3.35%
27,429
– –
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.11M 2.55%
78,900
– –
TERN
11
DELISTED
Terns Pharmaceuticals
TERN
$6.25M 1.96%
714,285
– –
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$4.43M 1.39%
23,014
– –
AURA icon
13
Aura Biosciences
AURA
$799M
$3.62M 1.14%
293,333
– –
WHWK
14
Whitehawk Therapeutics
WHWK
$232M
$3.6M 1.13%
526,329
– –
EQ icon
15
Equillium
EQ
$134M
$3.34M 1.05%
4,447,308
– –
HLTH
16
DELISTED
Cue Health Inc. Common Stock
HLTH
$3.32M 1.04%
8,980,909
– –
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
$2.98M 0.93%
36,171
– –
SCYX icon
18
SCYNEXIS
SCYX
$51.6M
$1.64M 0.51%
69,444
– –
ACET icon
19
Adicet Bio
ACET
$74.1M
$1.23M 0.39%
31,604
-4,646
-13% -$410K
APGN
20
DELISTED
Apexigen, Inc. Common Stock
APGN
$814K 0.26%
1,894,551
– –
WGS icon
21
GeneDx Holdings
WGS
$2.08B
$617K 0.19%
103,604
– –
NBSE
22
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$92.5K 0.03%
50,000
– –
ATRC icon
23
AtriCure
ATRC
$2.01B
– –
-46,259
Closed -$1.92M
BYSI icon
24
BeyondSpring
BYSI
$35.8M
– –
-4,958,143
Closed -$5.55M
OWLT icon
25
Owlet
OWLT
$158M
– –
-64,171
Closed -$291K
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q2 2023 Portfolio in Review

As of Q2 2023, Decheng Capital Management III (Cayman) held 29 positions worth $319M, up 29% from $248M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Decheng Capital Management III (Cayman) deployed $46.8M of net new capital in Q2 2023, opening 5 new positions and adding to 1 existing holding. Its largest new stake was ACELYRIN: 1,554,417 shares worth $32.5M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 79% a quarter earlier.

On the sell side, the largest reduction was Adicet Bio, an estimated $410K trimmed.

  • Decheng Capital Management III (Cayman)'s largest Q2 2023 buy was ACELYRIN: 1,554,417 shares worth $32.5M.
  • Decheng Capital Management III (Cayman) added most to Zentalis Pharmaceuticals in Q2 2023, an estimated $6.6M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q2 2023 reduction was Adicet Bio, cutting an estimated $410K.
  • Decheng Capital Management III (Cayman) fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 85% of its $319M portfolio in Q2 2023.
  • Decheng Capital Management III (Cayman) opened 5 new positions and closed 4 in Q2 2023.
  • Decheng Capital Management III (Cayman)'s portfolio value rose 29% quarter-over-quarter to $319M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q2 2023, filed 28 Jul 2023.